Table 1.

Demographic and clinical information of parkinsonian patients with COVID-19.

Patient	Sex	Age	PD duration	Comorbidities	PD Therapy	Institutionalization	COVID-19 symptoms	Worsening of PD	Change of PD therapy	Outcome
1	F	64	5	Hypertension	Levodopa/carbidopa, Pramipexole	No	Fever, Asthenia, Muscle pain	No	No	Recovery
2	M	77	20	Lung neoplasm (steady - in follow-up)	Levodopa/carbidopa	Yes	Fever, Asthenia, Cough, Dyspnea	Yes: dysphagia and inability to stand	Yes: stopped after infection worsening	Death
3	F	74	3	Depression	Levodopa/benserazide, Pramipexole	No	Fever, Asthenia, Muscle pain	Yes: worsening of rigidity and bradykinesia	No	Death
4	M	63	21	Diabetes in diet therapy	Melevodopa/carbidopa	Yes	Fever, Dyspnea	Not assessable: patients already bedridden and fed with PEG	No	Death
5	F	81	16	Hypertension, hyperhomocysteinemia	Levodopa/carbidopa gel intestinal infusion, Entacapone	No	Fever, Dyspnea	Yes: onset of disabling dyskinesia	No	Death
6	M	79	15	NA	Levodopa/carbidopa	NA	NA	NA	NA	Death
7*	M	80	5	Hypertension, atrial fibrillation, benign prostatic hyperplasia	Levodopa/carbidopa	Yes	Fever, cough	Yes: in particular worsening of dysphagia	Yes: increase in levodopa dose	Recovery
8	M	NA	NA	NA	NA	NA	NA	NA	NA	Death

PEG: percutaneous endoscopic gastrostomy.

NA: information not available.

*The patient reported some atypical parkinsonian symptoms/signs.

Caregivers of patients #6 and #8 did not accept to disclose further information, except those reported in the Table.